Cayman Spla2 (Type V) Inhibitor Screening Assay Kit; Size- 96 Wel

Phospholipase A₂ (PLA₂) catalyzes the hydrolysis of phospholipids at the sn-2 position yielding a free fatty acid and a lysophospholipid. The release of arachidonic acid from membrane phospholipids by PLA₂ is believed to be a key step in the control of eicosanoid production within the cell. Mammalian tissues contain many secretory PLA₂s (sPLA₂s), including types IB, IIA-F, III, V, X, and XII of which Type V sPLA₂ is involved in eicosanoid formation in inflammatory cells, such as macrophages and mast cells.^, It has been demonstrated that human type V sPLA₂ can bind phosphatidylcholine (PC) membranes and hydrolyze PC substrates much more efficiently than human type IIA sPLA₂, which makes it better suited for acting on the outer plasma membrane. Selective targeting and inhibition of sPLA₂s has been problematic as evidenced by the lack of availability of isozyme-specific inhibitors. The Cayman Chemical sPLA₂ (Type V) Inhibitor Screening Assay is a convenient colorimetric assay designed for rapid screening of Type V sPLA₂ inhibitors in a 96 well format. The sPLA₂ (Type V) Inhibitor Screening assay kit includes sufficient human recombinant Type V sPLA₂ for a minimum of 100 reactions. Identification of selective sPLA₂ inhibitors will offer substantial aid in the elucidation of the specific physiological function of each sPLA₂. Each kit contains assay buffer, DTNB, diheptanoyl thio-PC, human sPLA₂, a 96 well plate, plate cover, and complete instructions.

Needed but not supplied:Please to verify if (Milli-Q or equivalent) or any other components are needed for this assay.

WARNING This product is not for human or veterinary use.